AA
Andrew Arno
Director

Andrew Arno insider trades: Oncocyte (OCX) stock purchases

Director, Oncocyte Last trade Dec 26, 2024 59 Form 4 filings
$0
Sold, last 12 months
0 sales
$0
Bought, last 12 months
0 buys
13
Open-market trades
since 2011
6
Companies
last trade 2024

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Andrew reports to the SEC

Open-market buys and sales

13 trades reported on SEC Form 4, newest first

DateStockTypeValue
Dec 26, 2024OCX↑ Buy$26K
Apr 11, 2024OCX↑ Buy$100K
Jan 5, 2024XXII↑ Buy$17K
Dec 23, 2022OCX↑ Buy$88K
Aug 22, 2022SMSI↑ Buy$64K
Aug 17, 2022OCX↑ Buy$7K
Aug 17, 2022SMSI↑ Buy$12K
Aug 17, 2022SMSI↑ Buy$12K
Aug 17, 2022SMSI↑ Buy$12K
Aug 16, 2022OCX↑ Buy$144K
Sep 17, 2019OCX↑ Buy$108K
Jun 25, 2015AST↑ Buy$22K
Aug 25, 2011SMSI↑ Buy$87K

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

About Andrew Arno's insider trades

Andrew Arno is a director at Oncocyte (OCX). Since Aug 25, 2011, Andrew has reported 13 open-market purchases worth $699K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.

Their filings also include grants and awards (45 filings), shares withheld for taxes (1 filing), option exercises (1 filing), other transactions (1 filing). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every OCX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.